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a b s t r a c t
The Asian Prostate Cancer (A-CaP) Study is an Asia-wide initiative that has been developed over the
course of 2 years. The A-CaP Study is scheduled to begin in 2016, when each participating country or
region will begin registration of newly diagnosed prostate cancer patients and conduct prognosis in-
vestigations. From the data gathered, common research themes will be identiﬁed, such as comparisons
among Asian countries of background factors in newly diagnosed prostate cancer patients. This is the
ﬁrst Asia-wide study of prostate cancer and has developed from single country research efforts in this
ﬁeld, including in Japan and Korea. The inaugural Board Meeting of A-CaP was held on December 11, 2015
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at the Research Center for Advanced Science and Technology, The University of Tokyo, attended by
representatives of all participating countries and regions, who signed a memorandum of understanding
concerning registration for A-CaP. Following the Board Meeting an A-CaP Launch Symposium was held.
The symposium was attended by representatives of countries and regions participating in A-CaP, who
gave presentations. Presentations and a keynote address were also delivered by representatives of the
University of California San Francisco, USA, and the Peter MacCallum Cancer Centre, Australia, who
provided insight and experience on similar databases compiled in their respective countries.
Copyright © 2016 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The Asian Prostate Cancer (A-CaP) Launch Symposium took
place from 13:00 to 18:00 on December 11, 2015, at the Research
Center for Advanced Science and Technology, The University of
Tokyo and was attended by all members who had attended the
prior Board Meeting, from 10 countries and regions in Asia (China,
Hong Kong, Indonesia, Japan, Korea, Malaysia, Philippines,
Singapore, Taiwan, Thailand) and representatives of the University
of California San Francisco (USA) and the Peter MacCallum Cancer
Centre (Australia). The aim of the symposium was to mark the
launch of the A-CaP Study by providing an overview of the present
status of prostate cancer databases in Asia and discussing how each
country or regionwould proceedwith the A-CaP Study. Participants
from the USA and Australia provided information on similar data-
bases in their respective countries [Cancer of the Prostate Strategic
Urologic Research Endeavor (CaPSURE) and the Victorian Prostate
Cancer Registry (V-PCR)]. The following is a summary of the pro-
ceedings of the symposium.
2. Opening remarks
Hideyuki Akaza (Department of Strategic Investigation on
Comprehensive Cancer Network, The University of Tokyo)
expressed his pleasure to be able to welcome participants from 10
Asian countries, as well as from Australia and the USA. He noted a
brief history of the collaboration of Japan (J-CaP), Korea (K-CaP),
China (C-CaP), and CaPSURE.1
Yoshihiko Hirao (Osaka Gyoumeikan Hospital) expressed his
pleasure to be able to hold this launch symposium at the University
of Tokyo. He explained that from 2 years earlier, efforts had been
advanced towards the initiations of an Asian-wide collaborative
study. One of the key issues was acquiring ﬁnancial support and
Yoshihiko Hirao expressed his appreciation to Hideyuki Akaza for
working to amass funding. He expressed the hope that the meeting
would be fruitful and would mark a good start for A-CaP.
Choung-Soo Kim (Urology Cancer Center, Asan Medical Center)
thanked Hideyuki Akaza for his preparations for the launch of A-
CaP, noting that he has been a key ﬁgure inworking to highlight the
differences in cancer between Asia and western countries. One of
the key activities of A-CaP will be to create an Asia-wide database
and encouragemore andmore institutions across Asia to contribute
to a database. Another key issue for the future will be to give
consideration to how best use the Asian database. Although there
are still many challenges ahead, A-CaP is a most promising project
and the Korean side is ready to contribute fully to the advancement
of the A-CaP study and development of a database.
3. Seminar I: Present status of prostate cancer database study
Mototsugu Oya (Department of Urology, Keio University School
of Medicine), Dingwei Ye (Department of Urology, Fudan University
Shanghai Cancer Center), and Seiichiro Ozono (Department of
Urology, Hamamatsu University School of Medicine) chaired
Seminar 1.
3.1. Keynote speech: New ﬁndings from CaPSURE and introduction
to AQUA
Matthew Cooperberg (Departments of Urology and Epidemi-
ology & Biostatistics, School of Medicine, University of California
San Francisco) noted that the collaboration between CaPSURE and
J-CaP has been most rewarding and A-CaP promises to be a
paradigm-changing study.
In the USA, as in other western countries, there is an ongoing
drop in cancer mortality. The prostate cancer mortality rate has
fallen by half since the 1990s. However, across the world, cases are
still increasing, with 307,500 men dying from prostate cancer each
year, the ﬁfth most common cancer.
In terms of practice patterns in the CaPSURE register, data are
abstracted from CaPSURE, a national registry of men with prostate
cancer treated at up to 40 clinical practice sites, largely community-
based, across the USA. CaPSURE has included people with localized
disease since 1990, who have received treatment with radical
prostatectomy (RP), external-beam radiation therapy (EBRT),
brachytherapy, cryotherapy, watchful waiting (WW), active sur-
veillance (AS), or primary androgen deprivation therapy (ADT). Risk
stratiﬁcation is implemented via a well-validated Cancer of the
Prostate Risk Assessment (CAPRA) score. In terms of risk distribu-
tion over time, some of the ﬁrst papers documented risk migration.
Since the pre-prostate speciﬁc antigen (PSA) era, the risk has
plummeted and since the 2000s risk migration has stopped and
maintained at a steady rate. Surveillance is increasing in the real
world and from the dawn of the PSA era the rate of AS/WW has
increased signiﬁcantly. The other trend is in the category of treat-
ment of menwith high-risk disease. A majority of men now receive
RP.
In terms of trends for men older than 75 years there is still a
tendency towards under-treatment. In terms of variation in indi-
vidual practices there has been variation since 2010 across prac-
tices. There is a new registry called MUSIC, which is a statewide
registry in Michigan. The insurance company in Michigan has
providedmillions of dollars into this registry and they pay for a data
collector in every institution. Across the whole state, 49% of pa-
tients receive active surveillance. This represents a paradigm
change about how low risk disease is treated in the USA.
In terms of comparative studies, the results of ProtecT are
awaited and the results of other nonrandomized studies have been
issued recently. Very few studies have looked at brachytherapy.
Unadjusted cancer-speciﬁc mortality outcomes show that it takes a
very long period to identify outcomes. It takes 15e20 years to
identify differences between treatment modalities. The 15-year
cancer speciﬁc mortality rates by CAPRA score for various treat-
ments show that people with low risk disease do not have many
differences. However, people with high risk disease show a signif-
icant difference in predicted 15-year cancer-speciﬁc mortality
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depending on the kind of therapy received, whether it was RP,
primary ADT, AS/WW, EBRT, or brachytherapy. In US populations,
there is no role for ADT monotherapy for low-risk patients with
localized disease. There may be a completely different scenario in
Japan and Asia, however.
In the CaPSURE study, a little over 1% of people with low-risk
cancer died of prostate cancer. As of 2015 there are just over
15,000 men in the registry and 179 publications have been issued.
Up to 5,000 men are still followed actively. Continued follow-up for
clinical and quality of life endpoints and collection of archived
biospecimens for genomic analysis is being conducted. This part of
the study has been enabled by grant funding and is likely to be a
major focus for further research. CaPSURE will be collecting data
from more and more domains in the future.
American Urological Association (AUA) Quality Registry (AQUA)
is a new registry run by the AUA and the rationale is that prostate
cancer requires clinical data, ideally collected prospectively. Exist-
ing clinical registry efforts have excellent track records in research
and quality improvement, but are based on manual data collection
and are difﬁcult to scale. The key principles of AQUA are to use
software (provided by FIGMD) to minimize data entry burden. Data
ownership is by individual practices and the AUA only. Practice-
level data will be shared only with individual practice, bench-
marked against the aggregate data. No practice will see any other
individual data. Patient-reported outcomes (PROs) will also be
incorporated.
If the data are in the system as a structured data element, data
extraction is simple. However, the Gleason score does not exist in a
structured data format at present. However, there are natural lan-
guage processing algorithms that enable the extraction of data from
physician's notes, etc. AQUA was launched last year and there are
now 660 urologists across 80 practices participating in the study.
There is good geographic and practice-type diversity. For each
quality measure, the practices can see where they are relative to an
established benchmark and other participating practices on a
dashboard.
There are three large community-based urology groups that will
be administering PROs nationally. A patient dashboard will need to
be added to the website that is being developed to enable PROs.
From the ﬁrst 16 practices in AQUA it has been possible to identify
194,415 unique patients, with 4,911 prostate cancer patients be-
tween 2014 and 2015.
CaPSURE has paved the way for US registry efforts in urology
and other disciplines. The future must be collection of data from all
men with prostate cancer, routinely at the point of care using
automated systems. Data collection should include patient-
reported outcomes. Integrating genomics will drive personalized
medicine and answer questions, such as why prostate cancer varies
internationally. PROs are no longer a research tool in the USA but a
means of establishing the levels of quality of treatment. The A-CaP
is an extraordinary effort and CaPSURE is honored to be a part of it.
3.1.1. Discussion
Shiro Hinotsu (Center for Innovative Clinical Medicine, Okayama
University Hospital) noted that the presentation had included
various data and asked about future prospective studies to collect
parameters on comorbidity. Matthew Cooperberg responded that
the competing risks analysis reﬂects comorbidities. It may be the
case that menwith comorbidities will suffer more side effects from
treatment. The question of whether ADT causes cardiac disease is
tremendously controversial, although nonrandomized studies have
indicated that it does not. Questions about comorbidities are
complex and there will be always confounding factors that cannot
be accounted for.
Byung Ha Chung (Department of Urology, Gangnam Severance
Hospital, Yonsei University College of Medicine) referred to the
automated data retrieval system by an Indian company. Matthew
Cooperberg responded that AUA has provided an initial budget for
the ﬁrst 5 years. Urology is the third national specialty in the USA,
following cardiology and ophthalmology. In the long term it is
considered that there will be enough value created that urologists
will provide a participation fee. The hope is that there is going to
be so much value that government and pharmaceutical companies
will pay to conduct analysis using the registry. So far, no efforts
have been made to recruit participants actively and the groups
that have joined so far are just those that have expressed an in-
terest. It will take many years before all urologists in the USA join
the registry. It was noted that public reporting of data is now
becoming a reality and if it is not controlled it will be done to us
rather than by us.
3.2. J-CaP (Japan)
Shiro Hinotsu reported that the J-CaP 2001 study aimed to
evaluate the trends and outcomes of hormone therapy for estab-
lishing an adequate guideline for hormone therapy in Japan. Data
were collected using a secure server, with each institution inputting
the data themselves. Over the course of 5 years a total of 26,272
patients were enrolled in the secure server. In terms of eligibility
the patients were those who had been diagnosed by biopsy and
who had started primary hormone therapy. In total, 19,409 cases
were analyzed.
Initial hormone therapy was classiﬁed into various categories:
antiandrogen (AA) monotherapy; surgical castration (SC) luteiniz-
ing hormone-releasing hormone agonist (LHRH) monotherapy;
LHRH plus short-term AA; SC plus AA (SCþAA), LHRH plus AA;
WW; and others. Approximately 60% of patients who started initial
hormone therapy between 2001 and 2003 in Japan received
LHRHþAA or SCþAA. Progression free survival was updated on
September 30, 2014 and the median survival time is 4.94 years.
Overall survival is 12.2 years.
There was a subgroup of patients who died from a cardiovas-
cular event and these ﬁgures have been used to demonstrate that
hormonal therapy did not increase cardiovascular events in
patients.
In terms of cancer-speciﬁc survival in each cohort by J-CAPRA
score, patients in J- CaP had a better cancer-speciﬁc survival that in
the CaPSURE study.
A further study was the IS-1 study, which concentrated on pa-
tients with localized cancer (T1c or T2N0M0) who selected either
hormone therapy or prostatectomy. A further study was J-CaP
Surveillance 2010, which was conducted 5 years ago with the
objective of seeing the time trend of patient characteristics at the
diagnosis of prostate cancer and the time trend of initial treatment,
using the datasets of the Japanese Urological Association from 2000
and 2004 for comparison.
In terms of the characteristics of J- CaP database, it can be
summarized that the database contains long-term follow-up data
(up to a maximum of 13.5 years) from a large number of registered
patients. Data are provided by many hospitals in Japan. However,
limitations of the J-CaP database are a lack of data on details of
treatment change, PSA value during treatment and incomplete data
on Gleason scores. With regard to further follow-up and new
studies, a follow-up data collection of the IS-1 study and detailed
analysis of J- CaP 2010 surveillance was implemented and a data-
base of real world outcomes in Japan has been created. New
observational studies will use a data structure consistent with J-CaP
2001, IS-1 and J-CaP 2010. The ethical committee of Okayama
University has approved the new study protocol.
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3.2.1. Discussion
Dingwei Ye asked what the most difﬁcult part of maintaining a
database had been for such a long time, noting that C-CaP had only
recently started its own efforts and would like pointers concerning
the way forward. Shiro Hinotsu responded that 15 years ago the
computer system and network environment was completely
different. Survivor data were essential and, although there were
limitations in 2000, the data collection environment has been
transformed and it is important to continue to maintain efforts to
ensure data quality.
3.3. K-CaP (Korea)
Ji Youl Lee (Department of Urology, St. Mary's Hospital, The
Catholic University of Korea) noted that there are the Big Five
hospitals in SeouldSeoul National University, Asan Medical Hos-
pital, Samsung Seoul Hospital, Seoul St Mary's Hospital, and Yonsei
Medical Center, from which cumulative data have been collected
and delivered to the Korea Prostate Bank. Using the Korea Prostate
Bank database, many papers have been published, including most
recently a paper in European Urology in 2015 titled Prostate cancer
registries: current status and future directions.2
A smart prostate cancer database is needed in Korea. This is
needed because it is essential to have a common database struc-
ture. It is necessary to analyze the treatment outcomes of prostate
cancer, including active surveillance, focal therapy, etc. It is also
important to engage in analysis between clinical and basic research
data, including biobank data, clinical data, and genomic proﬁles.
Excel ﬁles will not be sufﬁcient for big data analysis and open
source software will be required, using cloud servers for ease of
access.
The Multicenter Prostate Cancer Registry system in Korea uses
three methods of data collection for prostate cancer: Excel on pa-
per; a web based electronic case report form system; and clinical
data warehouse system. Another important factor for data man-
agement is visualization tools. The Prostate Cancer Research
Network has amassed a total of 8,510 patients to date. The database
is mainly based on RP, in contrast to the J-CaP database. A prostate
cancer committee has been established among the major hospitals
and this committee makes decisions on who may use the joint
database to engage in analysis.
There is an international consortium plan in Korea, under which
if countries or institutions seek to use the Korean database system
they may do so for a small maintenance fee, with the system using
an open source database structure for facilitating international
collaboration based on cloud servers. This Smart Prostate Cancer
Database system is available in three languages and has been used
on a pilot basis by Hong Kong and Indonesia. Clinical and basic
cancer research in the near future will incorporate medical infor-
matics (big data) with bio banking and genomic proﬁling (nano
data), which, it is anticipated, will result in the realization of
personalizedmedicine. Korea is also in the process of developing an
electronic genomic medical record system.
In terms of the future for the A-CaP study, it would be preferable
to move towards a clinical decision-supporting system, including a
clinical databaseebiobankingegenomic database integration sys-
tem, which could help lead development towards the realization of
personalized medicine.
3.3.1. Discussion
Shigeo Horie (Department of Urology, Juntendo University
Graduate School of Medicine) noted that the presentation had
been very wide-ranging. He asked about confounding factors and
how these could be incorporated into databases when consid-
ering the modalities for treatment. Ji Youl Lee responded that
data from a diabetic study had been accessed through data
mining. Big data always can provide the answer. The question is
how to ﬁnd the data that are needed and use them towards the
objectives of the K-CaP database. Clinical data alone are not as
useful anymore.
3.4. C-CaP (China)
Gang Zhu (Department of Urology, Beijing United Family Hos-
pital and Clinics) noted that there was an urgent need for a
database similar to J-CaP, K-CaP, and CaPSURE in China. According
to the National Central Cancer Registry of China 2015 annual
report, the overall incidence of prostate cancer was 7.1/105 pop-
ulation in 2011. This ﬁgure ranked ninth in the highest cancer
incidences for all sexes and seventh in men.3 In response to this
need, Na Yanqun proposed to establish the Chinese Prostate
Cancer Database after discussion with Hideyuki Akaza. The C-CaP
software design was initiated in September 2013. The aim of C-CaP
is to collect and manage Chinese prostate cancer patient data in
diagnosis, treatment, and follow-up, to provide good evidence for
better diagnosis and treatment of prostate cancer, to provide ed-
ucation materials to patients and to establish a platform for in-
ternational exchange. In C-CaP diagnosed prostate cancer, patient
data are being prospectively collected. Each C-CaP center can ac-
cess C-CaP software to manage and study its own patients for free.
The C-CaP committee issues Chinese data and participates in in-
ternational studies.
The starting point of C-CaP software is to serve C-CaP centers to
better manage and use their own prostate cancer patient data. C-
CaP software has been designed to be simple and convenient and
be easy to operate. The English version has recently been
completed and will be used in Hong Kong, Macao, and other loca-
tions. C-CaP was ofﬁcially announced and released to the public in
December 2014. Currently there are 73 C-CaP centers in China with
4,602 patients recruited. The main functions of C-CaP can be
summarized as being to set up a database, engage in follow-up,
check data, engage in analysis, and export data. C-CaP apps have
also been developed for both doctors and patients.
Challenges that still need attention include such issues as how
to effectively increase records submitted to the database. Another
key issue relates to legal issues and addressing the questions of
whether consent needs to be sought from every patient and how to
protect patient privacy. Testing of the developed apps is ongoing
with a view to deploying these apps fully in the future.
3.4.1. Discussion
Bannakij Lojanapiwat (Faculty of Medicine, Chiang Mai Uni-
versity) asked about system differences between K-CaP and C-
CaP. Gang Zhu responded that coding items are based on those of
J-CaP, making it easy to manipulate data and make data inter-
operable. It is also possible to abstract data directly and selec-
tively to facilitate operations. It is also possible to extract data in
Excel format.
Wun-Jae Kim (Department of Urology, Chungbuk National
Medical University Hospital) asked whether it was possible to
transmit personal information. Gang Zhu responded that personal
information is kept exclusively in the hospital where the patient
was registered and cannot be seen by anyone else.
Edmund Chiong (Department of Urology, University Surgical
Cluster, National University Health System, Singapore) asked about
legal consent and how C-CaP proposes to gain consent. Gang Zhu
responded that a consent form is being compiled and will be pro-
vided to patients. However, there should not be any concerns as no
patient data will be sold.
Akaza et al / A-CaP Study launch symposium 91
4. Seminar II: How to proceed with the A-CaP Study
How to establish with the A-CaP Study: perspectives in partici-
pating countries
5. Part I
Mikio Namiki (Graduate School of Medicine, Kanazawa Univer-
sity), Shigeo Horie and Byung Ha Chung chaired part I of seminar II.
5.1. Taiwan
Chung-Hsin Chen (Department of Urology, National Taiwan
University Hospital) talked about the best way to proceed A-CaP in
Taiwan. He noted that the best way would be to link to the estab-
lished database in Taiwan, of which there are two, the Taiwan
Prostate Cancer Consortium (TPCC) and Taiwan Cancer Registry
Database (TCRD). There are possible expected obstacles, which are
the low input rate for TPCC and limited parameters for TCRD.
There are approximately 5,000 newly diagnosed cases of prostate
cancer in Taiwan each year. In 2011 prostate cancer was the ﬁfth
leading cancer in men. The proportion of prostate cancer has
increaseddramatically, from1.85% in the early 1980s to 8.91% in2011.
From 1979 the government started to create a cancer registry.
The TPCC has its origins in the objective to make up the limitations
of the TCRD and include important clinical parameters. The TPCC
was established in 2012, with a total of 18 hospitals currently
participating, with 16,385 patients enrolled. The TPCC covers
almost all regions in Taiwan.
The Urological Oncology Committee receives data reports from
hospitals and provides TPCC whole cohort feedback to hospitals.
Database collection forms include personal basic data, risk factors,
initial clinical presentation, initial tumor status, initial treatment, AE
and response, and oncological and survival outcomes. There are a
total of 139 items. There is debate in Taiwan on how to deﬁne data. A
consensus meeting was held in November 2013 and it was deter-
mined that data shouldbebasedonDREandrecord additional stages.
The most common initial PSA is < 10 ng/mL, but 18% of patients
have a PSA of > 100 ng/mL. The most common cancer staging in
Taiwan is T2 (36%). In terms of cancer-speciﬁc survival there is no
speciﬁc difference between Stage 1 and 3 cancers, which is 98% for
5-year survival and 96% for 10-year survival. In terms of overall
survival, there is a greater difference between Stages 1 and 3,
although this could be due to the advanced age of patients with
highest cancer staging.
5.1.1. Discussion
Matthew Cooperberg asked about increased incidence and
asked if this is due to the aging of the population. Chung-Hsin Chen
responded that there is no prostate cancer screening system in
Taiwan, but more and more people are taking their own health
check-ups. Tong-lin Wu (International Medical Center, Kaohsiung
Veterans General Hospital) responded that although there is no
national screening urologists are required to provide a PSA test to
males that they see who are older than 50 years.
Mikio Namiki asked about the percentage of hospitals partici-
pating in the TPCC. Chung-Hsin Chen responded that 23 hospitals
initially indicated that they would participate, but to date only 18
have been inputting data.
5.2. Hong Kong
Ng Chi Fai (Division of Urology, Department of Surgery, The
Chinese University of Hong Kong) reported that prostate cancer is
now the third most prevalent cancer among men in Hong Kong. A
government-funded body is responsible for the management of
public health services in Hong Kong, which covers > 80% of care.
There is a clinical management system in Hong Kong that utilizes
electronic consultation notes and covers the entire territory. The
integrated records of patients are comprehensive and easy to access.
In terms of the HK-CaP database, preparation work has already
been implemented, with a view to participating in A-CaP. A pro-
tocol has been formulated with centers being invited and an online
database being constructed. The hospitals that are expected to
participate are located in all areas of the territory. The online
database input form includes a variety of items and it is still under
development. After seeing the K-CaP and C-CaP databases, these
will provide an excellent source of reference for future develop-
ment of the HK-CaP database.
5.2.1. Discussion
Hideyuki Akaza asked how Hong Kong would manage discrep-
ancies or differences between the A-CaP database and the proposed
HK-CaP database. Ng Chi Fai responded that the database is still
under construction and there is still time and scope to expand the
items that would be included. The database already includes the
basic items that would be required by A-CaP.
5.3. Indonesia
Lukman Hakim (Department of Urology, Airlangga University/
Dr. Soetomo General Hospital, Surabaya) reported that prostate
cancer is the sixth most prevalent cancer in the world. In terms of
the recent status of prostate cancer in Asia, he cited a report Pros-
tate cancer in Asia: a collaborative report,4 which was published in
the Asian Journal of Urology and included the results of a multi-
center longitudinal study in Indonesia. In terms of the mortality to
incidence ratio, this ratio is high in Indonesia in comparison with
other Asian countries. In terms of the epidemiology of prostate
cancer in Indonesia, a multicenter study of ﬁve tertiary hospitals
showed that the median age of diagnosis if 68 years and most pa-
tients are in their 60s and 70s at diagnosis. The median PSA at
diagnosis is 60.2 ng/mL. In comparison to the above-mentioned
report, a PSA level of over 20 ng/mL is signiﬁcantly greater in
Indonesia than in other countries covered in the report.
In terms of diagnostic methods, 81.4% of cases are conducted
using a biopsy. In terms of T and M staging there is a large pro-
portion of metastasis (M1c), which suggests that people in
Indonesia are reluctant to go to hospital if they feel unwell.
With regard to treatment modalities, the most common treat-
ment is orchiectomy (32.1%), followed bymedical castration (25.3%)
and radical prostatectomy (13.4%). The reason for the high rate of
orchiectomy is that patients tend not to return to hospital after
medical castration, so orchiectomy is utilized.
With regard to other studies, two tertiary care hospitals in
Jakarta engaged in a study from 1995 to 2013 and this study
showed that the median age of diagnosis was 68 years, with a
median PSA of 50.78 ng/mL. This study was consistent with the
report mentioned above. In terms of treatment modalities, 13.8% of
patients refused treatment in the Jakarta study, which represents a
problem for Indonesia. This is not due to monetary issues, as low
income people in Indonesia are now fully covered by the health
insurance system.
Survival analysis of 107 elderly patientswho underwent treatment
for localized or locally-advance cases in two tertiary hospitals in
Indonesia showedno signiﬁcant differences in the5-year survival rate.
In terms of treatment options for localized and locally advanced
prostate cancer, although there are no signiﬁcant differences
among Asian countries in hormonal therapy, there is a low use of RP
in Indonesia.
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Prostate cancer in Indonesia has been increasing in the last
decade. Locally advanced and metastatic disease are dominant. Pri-
mary ADT with or without radiotherapy is the most common treat-
ment for localized and locally advanced cancer. Surgical castration is
still commonly recommended for advanced cases, with RP being less
applied than in other countries in Asia, Europe, and the USA.
With regard to how to proceed the A-CaP study in Indonesia,
there are three cancer centers on Java IslanddBandung, Jakarta,
and Surabayadwhich each have several satellite hospitals. It will be
a challenge to include other hospitals in order to get a larger na-
tional picture. For the A-CaP study the three cancer centers on Java
Island will be participating, using their satellite hospitals. Regula-
tions in Indonesia allow physicians to work in up to three medical
institutions, which should provide more opportunities to gain
samples for the A-CaP study. The data items to be collected will be
in line with the proposal from J-CaP. It would be preferable for
website-based data collection on good clinical practice principles.
The ﬁrst A-CaP meeting is scheduled to take place in Indonesia in
February 2016.
5.3.1. Discussion
Shigeo Horie asked about ideas for implementing follow-up in
Indonesia. Lukman Hakim responded that, given the size of the
country, follow-up would be difﬁcult. Follow-up could be achieved
by offering incentives to patients to travel to hospitals (provision of
travel expenses, etc.), or, if necessary, providing home visits.
Hideyuki Akaza asked about the main reason for patients
refusing treatment. Lukman Hakim responded that in the past when
the national health insurance system was not effectively imple-
mented, there were cost issues that presented obstacles. In addition,
there is a cultural resistance to having surgery. Recently the national
insurance system has improved but the cost allocation for the family
member who accompanies the patient to hospital remains with
them during their hospitalization may need further attention.
5.4. Singapore
Edmund Chiong reported that prostate cancer is the third most
common cancer in Singaporemen. There are 28.5 cases per 100,000
men and it is the sixth leading cause of death. Prostate cancer
incidence has steadily risen over the years and mortality rates have
also steadily increased. There has also been some variation in
incidence andmortality among the various ethnicities in Singapore.
There are seven public hospitals (one under construction) in
Singapore, which are covered by four health systems. In terms of
existing resources there is a national cancer registry, the Singapore
Cancer Registry, but there is no comprehensive data collection on
investigative or treatment data. Prostate cancer databases exist
only in individual hospitals and academic institutions. Prostate
cancer studies have been implemented in Singapore, including
interventional trials, advanced prostate cancer observational
studies, post-ADT observational studies and a Movember database.
Three hospitals have indicated their readiness to participate in the
A-CaP study. Other avenues for recruitment of patients include
medical oncology and radiation oncology departments, other in-
stitutions in the country, and contact with academic societies, such
as the Singapore Urological Association.
In terms of challenges, the funding of research assistants could
be cited. Research assistants are currently grant funded rather than
being permanent staff. There will also need to be accurate follow-
up data and oversight. There is an opportunity that other obser-
vational and interventional studies may be competing with A-CaP,
causing research assistant and investigator fatigue. In addition,
time will be needed for contractual agreements between in-
stitutions and with A-CaP, on data sharing, which may delay the
timeline somewhat. There are strict data protection laws in
Singapore and the acquisition of consent and institute review board
(IRB) approval will also be an important issue.
5.4.1. Discussion
Shigeo Horie asked about metastatic disease in Singapore.
Edmund Chiong responded that there is no national screening
program, but there are an increasing number of health checkups
available, which contributes to the increase in diagnosed prostate
cancer incidence.
Hideyuki Akaza referred to the acquisition of consent and IRB
and asked how long it could take for IRB applications. Edmund
Chiong responded that IRB applications generally take 3 months.
There are other options of building a standing database within an
institution, but this would also require approval. Hideyuki Akaza
noted that the multiethnicity of the Singapore population could
make it an important source for data analysis. He asked about
treatment outcome differences among ethnicities. Edmund Chiong
noted that there is no evidence to suggest that some ethnicities
respond better to treatment than others. He noted that the bulk of
data is for Chinese ethnic people. The incidence of prostate cancer is
slightly higher among ethnic Chinese than other ethnicities.
5.5. Philippines
Jason L. Letran (Department of Urology, Cardinal Santos Medical
Center) reported that there is no detailed cancer database in the
Philippines. The most recent data available show that among the
number of new cases for the 10 most common cancers in 2010,
prostate cancer is the fourth most common.
In terms of prostate cancer management in the Philippines over
the last 25 years, before the 1990s there was no early detection
strategy in place and most cancers were detected in advanced
stages. From the 1990s to 2000s PSA came to be used more widely
and cancer was detected in earlier stages. From the 2000s onwards
there has been a rapid development in treatment, including
brachytherapy, cryotherapy, and laparoscopy.
There is a National Digital Rectal Examination Day in the
Philippines, which is held on the day before Fathers' Day each year.
On this day free consultations are provided nationwide and this
could be a good source of data for A-CaP. Each year, approximately
3,000 examinations are implemented. The Philippines Society of
Urologic Oncologists, Inc. is a special interest society with 13
foundingmembers and 104members. The vision of the society is to
lead organization in urological oncology in the Philippines. The
society seeks to create a Philippines Prostate Cancer Database. The
expected launch of this database is June 2016 and the objective is to
have a longitudinal observational study of patients diagnosed to
have prostate cancer in the Philippines.
The database will have the involvement of 11 training in-
stitutions and 20 private institutions. This would provide a good
source of patients for A-CaP. Urologists would provide methods of
screening, PSA values at diagnosis, diagnostic and pathological
Gleason score and stage, among other items. Although institutions
are not sufﬁciently advanced to cope with electronic data entry, it is
hoped to provide a data sheet with online data entry and a dedi-
cated data encoder. This is the template by which the Philippines
would aim to participate in the A-CaP study.
5.5.1. Discussion
Byung Ha Chung asked about workload in the Philippines, given
thevery small numberof urologists across thecountry. JasonL. Letran
responded that the situation is difﬁcult but the urologists work hard
around the country. Hideyuki Akaza asked about refusal of treatment
and asked if it would be possible to provide ﬁgures on this.
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6. Part II
Rainy Umbas (Faculty of Medicine, University of Indonesia),
Kazuhiro Suzuki (Department of Urology, Gunma University
Graduate School of Medicine), and Kazuo Nishimura (Department
of Urology, Osaka Medical Center for Cancer and Cardiovascular
Diseases) chaired part II of seminar II.
6.1. Malaysia
Teng Aik Ong (Division of Urology, Faculty of Medicine, Uni-
versity of Malaya, Kuala Lumpur) reported that there are 108
urologists in Malaysia, serving a total population of 30 million.
There is no up to date cancer registry in Malaysia, the most recent
ﬁgures available being for 2007. Prostate cancer is the fourth most
common cancer among men and is more prevalent in ethnic Chi-
nese. A large proportion (almost 40%) of prostate cancer patients
present with stage 4 metastatic cancer.
Urological services are provided by both the government and
private sector, including Ministry of Health hospitals and university
teaching hospitals, as well as private hospitals. After inquiring with
institutions about the possibility of participating in A-CaP, the
assistance of J-CaP, etc., will be required to facilitate approval from
the government for state-run hospitals. If government hospitals can
be covered, that would mean that the majority of regions and pa-
tients could be covered under the A-CaP study.
In terms of strategy, issues that need to be addressed include
concerns over patient consent, ethics approval, funding, leadership,
and moves to expand the scope of the study.
6.1.1. Discussion
Rainy Umbas asked about any envisaged challenges relating to
data collection. He asked whether it would be important to
formulate guidelines. Teng Aik Ong responded that the methods of
diagnosis and treatment are more or less the same across the
country and successful data collection will be reliant on the urol-
ogists themselves.
6.2. Thailand
Bannakij Lojanapiwat noted that although the incidence of
prostate cancer in Asia is lower thanwestern countries, the stage of
prostate cancer at diagnosis in Asia is higher than western coun-
tries. Prostate cancer incidence has been rising steadily in Thailand
over the last 2 decades, but is still very low compared to other Asian
countries. The ratio between mortality and incidence is high in
Southeast Asia in contrast to other countries in Asia.
Given the low incidence, PSA screening is not a routine practice
in Thailand. The test is usually implemented in patients who
complain of lower urinary tract symptoms or individual requests
for screening. In a study entitled Correlation and diagnostic per-
formance of the prostate-speciﬁc antigen level with the diagnosis,
aggressiveness, and bone metastasis of prostate cancer in clinical
practice (Prostate International)5 it was found that the patients'
average age was 68 years and the average PSA level for biopsy was
102 ng/mL. A positive biopsy result was found in 396 patients. The
study showed the prevalence of prostate cancer to be 35.39% and
the positive predictive value in the diagnosis of prostate cancer
when the PSA level was > 4 ng/mL to be 37.2%, which is a little
higher than in a pooled meta-analysis study (25%).
Transrectal ultrasound with a prostate biopsy is the recognized
procedure for a diagnosis of prostate cancer. Due to the high rate of
ﬂuoroquinolone-resistant bacteria in most hospitals in Thailand,
patients who have risk factors to develop sepsis should have rectal
swab cultures for antibiotic susceptibility testing before a
transrectal ultrasound with biopsy. Treatment of prostate cancer
depends on clinical risk classiﬁcations such as D'Amico risk
grouping or National Comprehensive Cancer Network risk
grouping. In Thailand, urologists usually classify the patients
following National Comprehensive Cancer Network guidelines
(Asian Version). Local Prostate cancer guidelines by Thai Urologic
Association were issued in January 2013.
The healthcare insurance system in Thailand provides full
coverage through four systems, the major one of which is the
Universal Coverage Scheme, covering 74.6% of the population. Life
expectancy and comorbidity are important factors in the valuation
and treatment of prostate cancer in Thailand. In real-life practice,
most treatment of localized prostate cancer in Thailand is a RP
including open RP, laparoscopic RP, and robot-assisted RP in any
risk classiﬁcation (low, intermediate, or high risk) of healthy pa-
tients younger than 70 years.
In terms of the A-CaP study it is anticipated that in collaboration
with the Thai Urologic Association, data collection will be imple-
mented in ﬁve large hospitals in Bangkok and one large hospital in
Chiang Mai and Songkhla.
6.2.1. Discussion
Rainy Umbas noted that the situation in Thailand is similar to
Malaysia and the Philippines. He asked about policies for follow-up
for 5 years or 10 years. Bannakij Lojanapiwat responded that there
should be no problem with follow up in university hospitals.
6.3. Taiwan
Tong-lin Wu reported that the existing databases in Taiwan
were created for academic purposes, but not on the basis of any
speciﬁc theme. The National Prostate Cancer Registry (NPCP) is run
by the Government, which pays for people to input data. The NPCP
is participated by 80 hospitals currently. Although the items to be
registered are not very comprehensive, nonetheless they tend to be
fully ﬁlled. In contrast, the TPCC is more comprehensive, but tends
to be less fully ﬁlled out.
The NPCP requires that patient data should be registered 1 year
after diagnosis, and the status must be updated every 3 years
thereafter. The median age of diagnosis in Taiwan is 74 years with
55% of all cases being T1 or T2. Currently there are a total of 19,285
registered patients, with the number registered rising steadily each
year. Among the treatments for prostate cancer EBRT accounts for
the largest percentage (44%), followed by ADT (29%) and tran-
surethral RP (22%).
In termsof the commitmentof Taiwan to joining theA-CaPStudy,
six tertiary medical centers will join and all PIs are KOL, with
experience in CaP-related trials. Taiwanwill contribute 1,500e3,000
cases over the course of 3 years. The A-CaP study protocol will be
strictly followed and Taiwan is willing to collaborate with any other
colleague wishing to use the Taiwan database.
6.3.1. Discussion
Kazuhiro Suzuki asked about the percentage of patients enrolled
in the national database. Tong-Lin Wu responded that approxi-
mately 95% of T1 and T2 patients are registered in the national
database. In addition, 98% of patients are covered by the national
health insurance.
6.4. Korea
Wun-Jae Kim noted that the reason that A-CaP is being imple-
mented to seek an answer to the question of whether the charac-
teristics of prostate cancer differ between races. The CaPSURE study
has a large cohort with all stages of CaP and has issued 179 research
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papers. In Asia, there are currently only national study groups,
including J-CaP and K-CaP, but until now there has not been any
uniﬁed study across Asia. CaPSURE is one of the leading prostate
cancer registries in the USA, although urology practices are over-
represented and radiology practices are underrepresented, with
only diagnostic and therapeutic studies ordered by participating
physicians being recorded. A-CaP is still in its incipient stages and
many things remain still to do.
When organizing A-CaP it will be important to consider ques-
tions such as: How to collect data? What kind of committee should
manage A-CaP?What kind of server should be used? How to decide
the topic for publication? There are already existing databases in
Asian countries, including J-CaP, K-CaP, and C-CaP databases. These
are nationwide longitudinal prospective cohort studies, with
detailed data on type of ADT. The K-CaP database is a compre-
hensive data base for CaP patients in Korea, including collection of
tissue specimens and urodynamic data. C-CaP has also recently
launched and other countries in southeast Asia are advancing
moves to create databases.
Another important issue will be the management of the server
for A-CaP. Itwill be important to use a common server for direct data
collection, which could be a cloud server, linking to each country's
server, although the ﬁnal details have still to be worked out.
In terms of committees, the A-CaP will include various com-
mittees. The Steering Committee will be presided over by the
President and comprise representatives from each country who
will attend general meetings. This committee will have to decide
what kinds of other committees will be required. The Committee
for Policy-making will be moderated by the president of A-CaP and
should be responsible for policy-making, management, and sur-
veillance. The Data Committee will be a very important committee,
responsible for collecting data from 10 Asian countries. Matters that
need consideration are whether each country needs to be repre-
sented and what kind of data (items) are required, including pre-
operative data, operation data, hormone therapy data, and
castration-resistant prostate cancer-related data. Sometimes it
may be necessary to change the items for A-CaP and the Data
Committee should be responsible for such matters. The Scientiﬁc
Committee will be responsible for determining research themes
and such matters as who will be in charge of speciﬁc topics for
publication.
6.4.1. Discussion
Hideyuki Akaza noted that more discussion will be required to
make A-CaP more robust. He thanked Wun-Jae Kim for his
presentation.
6.5. Australia
Declan Murphy (Division of Cancer Surgery, Peter MacCallum
Cancer Centre) reported on perspectives from Australia and New
Zealand. He noted that the paper Prostate cancer registries: current
status and future directions2 shows the beneﬁts and advantages of
registries. It was noted that it is pleasing to see that much of this
work to create registries is upand running in theAsiaePaciﬁc region.
Australia and New Zealand have very high incidence of prostate
cancer. The indigenous populations fare poorly in terms of survival
in both countries, which were reported in the BJU International last
year, and this is why Australia is interested in participating in the
broader Asian region.
There are two registries in Australia: the Victorian Prostate
Cancer Registry (V-PCR), which was established in 2008 and now
has 15,000 patients in the register; and the South Australia Prostate
Cancer Clinical Outcomes, which was established in 1998 and has
accumulated over 10,000 patients.
The goals of the V-PCR are to provide information on patterns of
care following diagnosis of prostate cancer, to monitor quality of
care and to provide a platform for further research of prostate
cancer. The registry is very successful at recruitment, with 90% of all
new prostate cancer diagnoses registered at 33 sites. There has
been 100% clinician opt-in and 98% patient opt-in.
In terms of the management of localized prostate cancer, AS is
the most used treatment for low risk cancer, and surgery is the
most popular option for intermediate risk cancer, similarly to the
USA, with robotic surgery being the most used. In terms of PROs,
urinary functions and sexual functions are the most reported.
Interestingly, radiotherapy patients report more trouble with uri-
nary function than surgery patients.
One of the reasons that clinicians like to participate is that the
registry sends regular reports to clinicians and hospitals, including
information such as mortality rate, positive margins, documenta-
tion of T stage in medical record, treatment for men with high risk
disease, no treatment for menwith very low risk disease, treatment
failure and biochemical recurrence at 24months. These reports can
be used by clinicians and hospitals, and are a good way to monitor
the quality of care provided to patients. The register and feedback
method has helped to achieve a 21% reduction in rate of low-risk
cancer undergoing active treatment since 2010. Many publica-
tions have been issued based on V-PCR. It is an excellent disease-
speciﬁc registry with almost population-level data capture. It pro-
vides a good platform to expand the registry nationally.
The South Australia Prostate Cancer Clinical Outcomes recruited
915 patients in 2014 and they have not issued many publications,
but they are a partner in the new national database, known as the
Prostate Cancer Outcomes Registry Australia and New Zealand
(PCOR-ANZ). This registry is funded by Movember Foundation,
which raised US$100 million over the past year and PCOR is one of
the key initiatives it is supporting. An award has been given to
establish the new database PCOR-ANZ. Data collection and IT as-
pects are already up and running and it is hoped that all cases in
Australia will be recorded on the new database. The PCOR-ANZ will
provide a bi-national, population-based registry using Interna-
tional Consortium for Health Outcomes Measurement data.
Movember are supporting a global effort to coordinate prostate
cancer outcome registries and it may be useful for A-CaP to align
with the Movember Foundation and perhaps seek funding.
6.5.1. Discussion
Kazuo Nishimura noted that the focus on quality was very
interesting. Declan Murphy responded that this is one of the gov-
ernment requirements as a means of improving quality of service
provision.
Peter Carroll [Departments of Urology and Epidemiology &
Biostatistics, School of Medicine, University of California San
Francisco (UCSF)] commented on tracking positive margins as a
quality indicator, noting that positive margins could have adverse
outcomes by encouraging clinicians to operate more on low-risk
patients. He pointed out that UCSF has experience of showing
that positive margins do not have the impact of other items.
Hideyuki Akaza noted that A-CaP has much to learn from the
experiences of Australia and the USA and that it will be a useful
source of comparison. He requested the continued support and
advice of Australia, noting that it is hoped an A-CaP symposium
could be held on an annual basis.
7. Special lecture: AS for early-state prostate cancerdUCSF
experience
Osamu Ogawa (Department of Urology, Graduate School of
Medicine, Kyoto University) chaired the special lecture.
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Peter Carroll noted that CaPSURE started in 1995 and it has been
astonishing to see how the rest of the world has raced forward in
the past 20 years. There is great enthusiasm and forward mo-
mentum occurring in Asia.
The goal of AS is to avoid or delay the costs of treatment without
compromising cancer care. This is based on the rationale that initial
assessment is reasonably accurate and monitoring is accurate and
identiﬁes subclinical progression at a time that initial treatment
options are still available and curative.
The over detection of prostate cancer is a risk of PSA testing. One
of the possible solutions is to reduce treatment of lower-risk tu-
mors or change screening guidelines so as to decrease over-
detection by not screening for low-risk disease.
A cohort at UCSF in 2015 has 1,400 patients enrolled with me-
dian follow-up of 53 months and median PSA of 5.3 ng/mL. There
are 82% low risk patients and 18% intermediate risk patients. At
UCSF, PSA testing is conducted at 3e4-month intervals, with
transrectal ultrasound at 6-month intervals and repeat biopsy at
12e24 months. The active triggers for invention include change in
PSA kinetics, progression on follow-up biopsy, patient anxiety and
clinical or radiographic evidence of local/distant progression.
In terms of upgrade-free survival, only about 20% of patients
have a major change in CAPRA risk at the time of repeat biopsy.
Treatment-free survival at 5 years is approximately 60% with
overall survival of 98%, with 100% prostate cancer speciﬁc survival.
Approximately 270 patients in the cohort underwent radical
prostatectomy. A matched analysis shows that patients who pro-
gressed to 3þ4 compared to those diagnosed with 3þ4. In terms of
PSA-free survival there is no different among the cohort.
At UCSF it is thought that AS is appropriate for younger men. It
turns out that younger patients have lower progression rates than
older patients. Three-year and 5-year upgrade-free survival rates
are 73% and 55%, respectively, versus 64% and 48% in the overall
cohort. Young patients are more likely to receive subsequent
treatment with RP (26%) versus radiotherapy (7%). There is no
signiﬁcant association between younger age and time to treatment
or biochemical recurrence following delayed RP.
PSA is not a good predictor for upgrading. The PSA itself remains
stable relatively early in surveillance. One of the strongest predi-
cators of treatment is actually PSA density, which is a better pre-
dictor of treatment and reclassiﬁcation than PSA.
With regard to serial imaging during AS, there are few reports of
longitudinal radiographic progression during AS. In the experience
of UCSF, 974 low and intermediate risk patients managed with AS
receiving serial high resolution biplanar TRUS 228 eventually un-
derwent RP. Progression by initial TRUS stage shows a change in the
volume over time.
In tissue-based gene expression testing, UCSF has worked with
various companies, including a quantitative 17-gene reverse tran-
scriptionepolymerase chain reaction assay on manually micro-
dissected tumor tissue from needle biopsy. Using the Oncotype DX
Genomic Prostate Score (GPS) shows a wide distribution of GPS at
each level of clinical risk. There is improved risk discrimination
with addition of GPS to CAPRA. Serial oncotype testing on AS has
been implemented and 98 men identiﬁed who underwent serial
GPS testing. There was no difference with the GPS scores, even at
the time of upgrade.
There is big interest in multiparametric magnetic resonance
imaging (MRI) in the USA and the UK. MR targeted biopsy offers the
potential to combine the anatomic and biological insights afforded
by high resolution prostate MRI with real-time ultrasonographic
guidance. There is enthusiasm for MR/ultrasound fusion-guided
biopsy with ultrasound guided biopsy for the diagnosis of pros-
tate cancer. Fusion biopsy helps to identify higher risk cancers.
In terms of anticipated opportunities and challenges for MRI
fusion biopsy there are variable techniques and variable experience
and there are also concerns about cost effectiveness. Comparing
patients who had the fusion biopsy compared to the systematic
biopsy, 12 patients (13%) were identiﬁed with upgraded cancers.
Future avenues of investigation include the outcomes at subse-
quent biopsy following initial fusion MR biopsy, impact on risk
stratiﬁcation and cost considerations.
In terms of anxiety, depression and distress in RP versus AS, it has
been shown that AS patients do not suffer abnormally from depres-
sion or anxiety. In terms of urinary function in low-risk disease, there
is a change afterRP, followedbygradual recovery, butnot quite topre-
treatment function. In terms of sexual function it is important to note
that sexual function declines with age, so RP and AS sexual function
outcomes grow closer together as time progresses.
There is concern that focal therapy could lead to greater treat-
ment being provided to low-risk patients. This is an issue that will
require monitoring. In addition, online disease-management tools
online are being developed for patients to report their outcomes and
provide support. This is a trend that will require further attention.
7.1. Discussion
Declan Murphy asked about offering AS to younger men with
intermediate risk. Peter Carroll noted that UCSF is careful to explain
the risks and weigh up the alternatives. He noted that he was very
concerned about relentless grade migration worldwide. In younger
patients there are MRI testing and yearly fusion biopsies available,
from which a low-risk cancer can be identiﬁed.
Osamu Ogawa asked about best follow-up protocol for AS. Peter
Carroll responded that it is thought that AS can be made much
more efﬁcient and some patients may not need further biopsies,
depending on their level of risk. The tendency is to see patients at 3-
month intervals, but there is a feeling that this could be made more
efﬁcient and intervals further extended.
8. Closing remarks
Taiji Tsukamoto (Department of Urology, Sapporo Medical Uni-
versity) thanked all the participants for their input in the sympo-
sium and expressed his appreciation to Hideyuki Akaza for leading
efforts to launch A-CaP.
Peter Carroll also thanked Hideyuki Akaza for organizing a
wonderful symposium and expressed his expectations for a
wonderful Asia-wide collaboration through A-CaP.
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